Autres langues Vaxart, Inc.

Actions

VXRT

US92243A2006

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
0,7097 ^USD	+7,79%		-6,07%	+23,90%

14/03	Vaxart, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
14/03	Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3	27/03
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20/03
Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results	14/03
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14	07/03
Vaxart Appoints Steven Lo as Chief Executive; Shares Fall	06/03
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director	06/03
Vaxart, Inc. Announces Chief Executive Officer Changes	06/03
Vaxart, Inc. Announces Management Appointments	06/03
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge	05/02
North American Morning Briefing : Stock Futures -2-	01/02
Vaxart Secures $9.3 Million Award for Phase 2b COVID-19 Pill Study	19/01
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate	19/01
Vaxart to Raise $10 Million From RA Capital Management; Shares Rise	16/01
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management	16/01
Vaxart, Inc. Announces Management Change	16/01
Vaxart, Inc. Announces CEO Changes	16/01
Vaxart, Inc. Announces Resignation of Andrei Floroiu as President and Director	16/01
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers	21/12
Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers	21/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Vaxart, Inc.

Actions

VXRT

US92243A2006

Autres langues

Filtres